INTRODUCTION
Osteosarcoma is the most common human primary bone malignancy, accounting for over 700 new diagnoses in the United States each year. Current multimodality therapy consists of radical surgery and systemic chemotherapy. 1, 2 Despite improvements in outcome over the past 30 years for patients with local disease, the 5-year survival rates for patients with metastatic disease at presentation or recurrent disease remain poor. 3 e human epidermal growth factor receptor 2 (HER2) is expressed in up to 60% of primary osteo sarcoma samples and correlates with poor outcome. [4] [5] [6] [7] [8] [9] [10] [11] [12] HER2 is a validated target for breast cancer immunotherapy. [13] [14] [15] [16] However, the expression of HER2 on osteosarcoma cells is low, rendering HER2 monoclonal antibodies like trastuzumab less e ective. 5, 17, 18 Genetic modi cation of T cells is an attractive approach to overcome this limitation because the overall avidity of receptors arrayed on a T cell will be greater than the avidity of a bivalent antibody, and engagement of a limited number of T-cell receptor molecules may be su cient to trigger a cytotoxic e ector response. [19] [20] [21] A HER2-speci c single chain variable fragment can be prepared as part of a chimeric antigen receptor (CAR), 17 and the aim of this study was to determine whether osteosarcoma expresses su cient HER2 to induce activation and proliferation of genetically modi ed T cells expressing such a HER2-speci c CAR that incorporated a CD28.ζ costimulatory/signaling domain. We evaluated the antitumor activity of these cells in vitro and in two xenogenic mouse models that mimic local and lung metastatic osteo sarcoma. 22 Our results show that genetic modi cation of T cells with a CAR can overcome the ine ectiveness of a monoclonal antibody (MAb) with the same speci city because HER2-speci c T cells, but not HER2 MAb, killed HER2-positive osteosarcoma cells ex vivo and in both in vivo models.
RESULTS

HER2 is expressed by osteosarcoma cells at low levels and HER2 monoclonal antibodies are ineffective
To con rm that HER2 is expressed by primary osteosarcoma cells, we analyzed HER2 expression in para n-embedded tissue Correspondence: Stephen Gottschalk, Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, Houston, Texas 77030, USA. Email: smg@bcm.edu sections as well as in osteosarcoma cell lines (Figure 1a,b) . Seven of eight serial tumor samples were positive by immunohistochemistry. All 12 osteosarcoma cell lines studied expressed HER2 as determined by uorescence-activated cell sorter (FACS) analysis. e level of HER2 expression was comparable to the low HER2 expressing breast cancer cell line MCF-7, whereas no cell line expressed HER2 at high levels equivalent to SK-BR-3. e therapeutic activity of HER2 MAb trastuzumab primarily relies on direct inhibition of the HER2 signaling cascade, reducing cell proliferation by consequent G1 phase arrest. 23, 24 In proliferation 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 10 0 10 1 10 2 10 3 10 4 assays, however, we found that trastuzumab failed to inhibit the proliferation of HER2-positive osteosarcoma cell lines even at a concentration of 500 μg/ml, which is eightfold higher than the mean steady-state therapeutic serum concentration obtained in human subjects (Figure 2a ). Because the antitumor e ect of the antibodies in vivo may also have a component dependent on complement mediated lysis, we added complement and increasing concentrations of trastuzumab to 51 Cr-labeled tumor target cells. Although the HER2 high expressing cell line SK-BR-3 was e ciently lysed, all ve HER2-positive osteosarcoma cell lines tested were resistant to lysis even at concentrations of trastuzumab that are several-fold higher than the levels achievable in human subjects and even when the more potent rabbit complement was substituted for human (Figure 2b ).
HER2-specific T cells secrete immunostimulatory cytokines and proliferate after exposure to HER2-positive osteosarcoma cells
To learn whether osteosarcoma cell lines express su cient levels of HER2 to be recognized by T cells, we generated HER2speci c T cells using a RD114-pseudotyped SFG retroviral vector encoding a CAR consisting of the HER2-speci c single chain variable fragment FRP5, a CD28 transmembrane domain and a CD28.ζ signaling domain (Figure 3a) . 17 A er transduction a median of 72% (range 45-92%) T cells expressed HER2.CD28.ζ CARs as judged by FACS analysis (Figure 3b) . Nontransduced (NT) as well as HER2-speci c T cells were incubated with a panel of osteosarcoma cell lines and a er 24-48 hours of coculture, interferon (IFN)-γ and interleukin (IL)-2 production was determined by enzyme-linked immunosorbent assay. HER2-speci c T cells only produced IFN-γ and IL-2 a er exposure to HER2-positive targets, indicating that cytokine production was dependent on the presence of HER2 antigen (Figure 4a,b) . HER2-speci c T cells cocultured with the HER2 high expressing cell line SK-BR-3 secreted more IFN-γ and IL-2 c than HER2-speci c T cells cocultured with HER2 low expressing osteosarcoma cell lines, consistent with reports by others that antigen density on target cells determines T-cell activation. 25 In addition, HER2-CAR triggering resulted in robust T-cell proliferation (P < 0.001; Figure 4c ). ese results show that osteosarcoma cells express su cient levels of HER2 to induce cytokine secretion and T-cell proliferation.
HER2-specific T cells kill HER2 expressing osteosarcoma cell lines in vitro
We next demonstrated that HER2-speci c T cells killed HER2positive osteosarcoma cell lines in a standard 51 Cr-release assay, whereas HER2-negative control cells (MDA-MB-468) were not killed (Figure 4d ). In addition, NT T cells did not kill any of the osteosarcoma cell lines, indicating that the killing of HER2positive osteosarcoma cell lines depended on the expression of HER2-speci c CARs.
Adoptive transfer of HER2-specific T cells results in regression of osteosarcoma in a SCID mouse model of locoregional disease
Having established that HER2 expressed on osteosarcoma is a target for HER2-speci c T cells ex vivo, we determined the in vivo antitumor activity of HER2-speci c T cells in a xenogeneic severe combined immunode cient (SCID) mouse model. To allow serial imaging, osteosarcoma LM7 cells were transduced with a retroviral vector encoding an eGFP-re y luciferase fusion gene (LM7.eGFP-FFLuc). Cells were sorted for eGFP expression, and FACS analysis con rmed that LM7.eGFP-FFLuc cells expressed HER2 at the same level as the parental cell line. Luciferase expression was con rmed ex vivo using luminometry (data not shown).
To investigate the antitumor activity of HER2-speci c T cells in vivo, SCID mice were injected intraperitoneally with 2 × 10 6 LM7.eGFP.FFLuc cells (day 0) and treated for three consecutive days with daily intraperitoneal injections of 10 × 10 6 HER2.CD28.ζ T cells. We tested two groups of mice: those with small (day 2) tumors, and those with large (day 8). Bioluminescence imaging showed a 10.5-fold di erence in photon emission between the day 2 and 8 malignancies (Figure 5b) . Although tumors in untreated mice grew aggressively, injection of HER2-speci c T cells induced tumor regression in 9/10 mice bearing small tumors and 7/9 mice bearing large tumors. To exclude nonspeci c antitumor activity of T cells, a subset of tumor-bearing mice were injected with NT T cells on day 2 for three consecutive days. ere was a brief, transient decrease in photon emission before the tumors started to grow at the same rate as in nontreated animals, indicating that the eradication of LM7.eGFP.FFLuc cells was dependent on HER2. CD28.ζ CAR expression.
Quanti cation of bioluminescence signals showed no di erence between groups before treatment (Figure 5b) but a statistically signi cant di erence between the HER2-speci c T-cell groups and the control groups (NT T cell and tumor only) from day 4 a er T-cell injection. is di erence was maintained therea er (P < 0.002 for mice with small tumors and P < 0.008 for mice with large tumors). Hence, HER2-speci c T cells have potent antitumor activity a er local delivery in vivo.
All groups of mice were followed long-term with bioluminescence imaging (Figure 5c ). Survival analysis at day 160 showed that mice from the untreated and NT T-cell control groups had a median survival of 63 days (range 29-66 days) and 65 days (range 49-104 days), respectively. Injection of HER2speci c T cells into mice bearing small or large tumors produced signi cant survival advantage; mice bearing small tumors had a median survival of >160 days (P < 0.001) whereas mice with large tumors had a median survival of 88 days (range 62 to >160 days; P < 0.01).
Regression of osteosarcoma lung metastases after adoptive transfer of HER2-specific T cells
Having shown that local injection of HER2-speci c T cells results in eradication of tumor cells in vivo, we determined the antitumor activity of HER2-speci c T cells in a metastatic model, because osteosarcoma primarily metastasizes to the lung in humans. 26 We used the well-established LM7 metastatic model, 22 and injected tumor cells into the tail vein. is route established progressive lung metastases in 100% of mice, as judged by bioluminescence imaging. In untreated mice, tumors progressively grew in all animals (n = 5; Figure 6a ). In contrast, injections of HER2-speci c T cells resulted in rapid regression of lung metastasis in all treated animals (n = 10). Eight of 10 animals had no evidence of tumor recurrence a er >6 months of follow-up. One animal had recurrent lung metastasis and one animal was euthanized because of a metastatic deposit in the forelimb. Survival analysis revealed a signi cant survival advantage (P < 0.001) in animals treated with HER2-speci c T cells (median 145 days; range 60-160 days) compared to untreated animals (median 65 days; range 36-89 days; Figure 6b ). Figure 5 Adoptively transferred human epidermal growth factor receptor 2 (HER2)-specific T cells induce regression of intraperitoneal osteosarcoma xenografts. 2 × 10 6 LM7.eGFP.FFLuc cells were injected intraperitoneally in 9-to 12-week-old nonobese diabetic-severe combined immunodeficient mice (day 0) followed by intraperitoneal injection of 10 × 10 6 HER2-specific T cells or nontransduced T cells (NT T cells) on days 2, 3 and 4 or days 8, 9 and 10 after tumor inoculation. (a) Although tumors regressed over a period of 24-72 hours in response to injection of HER2-specific T cells (two lower rows), tumors grew progressively in untreated mice as shown for four representative animals and in mice receiving nontransduced T cells (upper two rows). (b) Quantitative bioluminescence imaging: the pretreatment bioluminescence values on day 2 were comparable between animals treated with HER2-specific T cells and those treated with NT T cells (P = 0.94). As early as 24 hours after initiation of treatment, the median photon emission from animals receiving HER2-specific T cells was significantly lower than those receiving NT T cells and for untreated tumors (P < 0.002 and P < 0.008 for animals treated on day 2 and those treated on day 8, respectively). Values are corrected to background bioluminescence. Two-tailed P value, Mann-Whitney U test are reported. Solid arrows: time of T-cell injection. (c) Survival analysis was performed at day 160. Mice from the untreated and NT T-cell control groups had a median survival of 63 days (range 29-66 days) and 65 days (range 49-104 days), respectively. Injection of HER2-specific T cells into mice bearing small or large tumors resulted in a significant survival advantage; mice bearing small tumors had a median survival of greater 160 days (P < 0.001) where as mice bearing large tumors had a median survival of 88 days (range 62 to >160 days; P < 0.01).
DISCUSSION
e development of e ective immunotherapies for osteosarcoma is hampered by the limited number or low expression of known target antigens and at present there are no published preclinical studies that have been able to show antitumor activity from antigen-speci c vaccines or adoptively transferred T cells in xenogra models of human osteosarcoma. Here we show that the low expression of the well-known target antigen HER2 can be exploited by genetically modifying T cells by expressing CARs derived from a MAb with the same speci city. Genetically modied T cells recognized and killed HER2-positive osteosarcoma cells in vitro. In addition, adoptive transfer of HER2-speci c T cells into xenogenic mouse models resulted in regression of local as well as metastatic disease.
Tumor-associated antigens expressed in osteosarcoma include HER2, MAGE and GAGE family members, NY-ESO-1, and papillomavirus binding factor. 6, 9, 11, 27 Among these HER2 is the only antigen that is expressed in unprocessed form on the cell surface, which enables the use of T cells that are genetically engineered to express HER2-speci c CARs. 4, 7, 18 Conceptually, CAR expressing T cells have several advantages over conventional antigen-speci c T cells. 28 In contrast to the lengthy process of generating conventional tumor antigen-speci c T cells ex vivo whose frequencies are o en <1 per 1,000 T cells, CAR expressing T cells can be prepared readily in large quantities by mitogen activation of all T cells. 28, 29 Moreover, CARs recognize antigens in a major histocompatibility complex unrestricted manner, rendering T cells immune to some of the major mechanisms by which tumors like osteosarcoma avoid major histocompatibility complex-restricted T-cell recognition. 28, 29 We showed in agreement with others that HER2 is expressed in primary tumors as well as osteosarcoma cell lines, however expression was low. 18 Clinical studies have demonstrated that HER2 MAbs have no antitumor activity in patients with malignancies that express low levels of HER2 equivalent to those seen in human osteosarcoma. 20 Our in vitro studies con rm this for osteosarcoma, because HER2 MAbs neither inhibited cell proliferation nor induced complement mediated cell lysis, even at concentrations almost 1 log higher than those used in humans. Nonetheless, HER2 expression was su cient for T-cell recognition, and our HER2-speci c T cells expressing a CAR with a CD28.ζ signaling domain were able to lyse osteosarcoma cells in vitro and in vivo. CARs with a CD28.ζ signaling domain are superior in activating T cells a er antigen exposure than CARs containing a ζ signaling domain. [29] [30] [31] [32] [33] CD28 signaling is critical for providing co-stimulation a er initial T-cell activation and incorporation of the endodomain of CD28 into CARs results in enhanced T-cell proliferation and IL-2 secretion. [29] [30] [31] [32] [33] HER2-speci c T cells not only killed HER2positive tumor cells, but also secreted IFN-γ and IL-2, and proliferated a er coculture with HER2-positive tumor cells. We tested the antitumor activity of HER2-speci c T cells in two animal models. In our rst model, we showed that HER2speci c T cells induced regression of locoregional osteosarcoma in 9/10 mice with small tumors and 7/9 mice with large tumors. e antitumor e cacy of HER2-speci c T cells was lower in the large tumor group, likely re ecting a lower ratio of T cells to tumor cells at the time of therapy in comparison to mice with small tumors. 34, 35 e inclusion of additional signaling domains, such as 4-1BB (CD137) or OX40 (CD134), in antigen-speci c CARs or genetically engineering T cells to secrete cytokines such as IL-2 or IL-15 may further enhance the antitumor activity of T cells. 30, 31, 36, 37 Li et al. recently demonstrated that murine sarcoma cells, genetically engineered to express human HER2, can be targeted with murine T cells expressing HER2-speci c CARs. 21 Our human study is consistent with these observations in mice, and shows activity against human osteosarcoma cells, in which the expression of HER2 had not been genetically manipulated. HER2-positive osteosarcoma cells obtained directly from tumors cannot be tested in these functional assays due to the limited availability of tissue and their growth characteristics in vitro. We were, however, able to characterize the expression of HER2 using immuno histochemistry of primary para n-embedded osteo sarcoma sections and observed HER2-positivity in seven out of eight samples. Although our locoregional model demonstrates the in vivo antitumor activity of injected HER2-speci c T cells, its clinical relevance is limited because the majority of osteosarcomas occur in the extremities where aggressive surgical approaches are feasible and result in excellent local control (albeit with severe aesthetic and functional limitations). Nevertheless, achieving tumor free resection margins remains a challenge for bulky disease, and the local activity of T cells might allow limb sparing procedures for tumors which otherwise would have required amputations.
Our metastatic lung model is closer to the pattern of human disease, because lung metastases contribute signi cantly to the morbidity and mortality of osteosarcoma. In total, 20% of patients have bilateral lung metastases at diagnosis and >95% of patients have lung metastases on postmortem examination. 26, 38 In the well-established LM7 xenogenic lung metastases model, 22 adoptive transfer of HER2-speci c T cells resulted in regression of lung metastases and a signi cant survival advantage of tumorbearing mice.
HER2 MAb may have o target e ects, the most concerning of which is the poorly understood cardiac toxicity. If HER2-speci c T cells are long-lived, this problem could be accentuated. Potential cardiac toxicities are di cult to model in mice because T cells that are speci c for human HER2 do not recognize murine HER2. Nonetheless, we have shown that HER2-negative cells are not killed by HER2-speci c T cells, and others have observed that two patients, who received HER2-speci c T cells had no cardiac toxicity (see ref. 39 and S. Gottschalk, N.Ahmed, C.M. Rooney, G. Dotti, H.E. Heslop, A.P. Gee et al., unpublished results). In addition, HER2 vaccines are well tolerated, and no cardiac toxicities were observed in patients, who developed HER2-speci c T-cell responses. 40 In summary, genetic modi cation of T cells with CARs in this study has overcome the ine ectiveness of a MAb to a weakly expressed tumor-associated antigen and provides a rationale for developing a phase I clinical study for patients with recurrent HER2-positive osteosarcoma. Other tumor-associated target antigens that may be unresponsive to monoclonal antibodies may be amenable to a similar CAR T-cell approach. e generation of LM7 cells, an Sa-OS derivative that has high metastatic potential to the lungs, was described previously. 22 All cell lines were grown in Dulbecco's modi ed Eagle's medium (Invitrogen, Carlsbad, CA) with 10% fetal calf serum (HyClone, Logan, UT), supplemented with 2 mmol/l GlutaMAX-I, 1.5 g/l sodium bicarbonate, 0.1 mmol/l nonessential amino acids, and 1.0 mmol/l sodium pyruvate (all media supplements from Invitrogen). T cells were maintained in RPMI 1,640 with 10% fetal calf serum containing 2 mmol/l GlutaMAX-I.
MATERIALS AND METHODS
Generation of retroviral constructs. e HER2-speci c CAR with a CD28.ζ signaling domain was constructed by subcloning the HER2-speci c single chain variable fragment FRP5 into a SFG.CD28.ζ retroviral vector containing a CD28 transmembrane and a CD28.ζ signaling domain. 41 A retroviral vector encoding the fusion protein eGFP-re y luciferase (eGFP.FFLuc) was used to generate re y luciferase-expressing LM7 cells (LM7.eGFP. FFLuc) for the in vivo studies. 17, 42 Retrovirus production and transduction of T cells. To produce retroviral supernatant, 293T cells were co-transfected with HER2-retroviral vector containing plasmid, Peg-Pam-e plasmid encoding the sequence for MoMLV gag-pol, and plasmid pMEVSVg containing the sequence for vesicular stomatitis virus G, using GeneJuice transfection reagent (EMD Biosciences, San Diego, CA). 29, 43 Supernatants containing the retrovirus were collected 48 and 72 hours later. Vesicular stomatitis viruspseudotyped viral particles were used to transduce the FLYRD18 producer cell line for the production of RD114-pseudotyped viral particles. 44 OKT3/CD28 activated T cells were transduced with retroviral vectors as described. 42, 43 Brie y, peripheral blood mononuclear cells were isolated by Lymphoprep (Greiner Bio-One, Monroe, NC) gradient centrifugation; 5 × 10 5 peripheral blood mononuclear cells per well in a 24-well plate were activated with OKT3 (OrthoBiotech, Raritan, NJ) and CD28 monoclonal antibodies (BD Biosciences, Palo Alto, CA) at a nal concentration of 1 μg/ml. On day 2, recombinant human IL-2 (Chiron, Emmeryville, CA) was added at a nal concentration of 100 U/ml, and on day 2 cells were harvested for retroviral transduction. For transduction, we precoated a nontissue culture treated 24-well plate with a recombinant bronectin fragment (FN CH-296; Retronectin; Takara Bio USA, Madison, WI). Wells were washed with phosphate-bu ered saline (PBS; Sigma, St Louis, MO) and incubated twice for 30 minutes with retrovirus. Subsequently, 3 × 10 5 T cells per well were transduced with retrovirus in the presence of 100 U IL-2/ml. A er 48-72 hours cells were removed and expanded in the presence of 50-100 U IL-2/ml for 10-15 days prior to use.
Flow cytometry. For all ow-cytometric analyses, a FACScalibur instrument (Becton Dickinson, Mountain View, CA) and CellQuest so ware (Becton Dickinson) were used. We analyzed data on >10,000 events; in all cases negative controls included isotype antibodies. Cells were washed once with PBS containing 2% FBS and 0.1% sodium azide (Sigma; FACS bu er) prior to addition of antibodies. A er 15-30 minutes of incubation at 4 °C in the dark, the cells were washed once and xed in 0.5% paraformaldehyde/ FACS bu er prior to analysis.
Tumor cell lines were analyzed with mouse anti-HER2 IgG (clone TAB250; Zymed, Carlsbad, CA) followed by a goat anti-mouse-Fc PE secondary antibody (Chemicon, Temecula, CA). T cells were analyzed with anti-CD8 FITC, -CD4 PE, and -CD3 PerCP (BD Biosciences).
To determine cell-surface expression of the HER2 CAR transgene, a recombinant HER2-Fc fusion protein (R&D Systems, Minneapolis, MN) was used. Bound HER2-Fc was detected with a goat anti-Fc FITC secondary antibody (Chemicon, Temecula, CA). 17 Proliferation assay. Tumor cells were cultured at 5,000 cells/well in a 96-well plate in the presence of increasing concentrations of trastuzumab. A er 4 days the cells were pulsed with 1 μCi (0.037 MBq) methyl- 3 [H]thymidine and cultured for an additional 18 hours. e cells were then harvested onto lters and dried; counts per minute were measured in a scintillation counter (TriCarb 2500 TR; Packard BioScience, Boston, MA). e experiments were performed in triplicate. Cells cultured without trastuzumab served as control.
Complement assay. 1 × 10 6 target cells were labeled with 0.1 mCi (3.7 MBq) 51 Cr and di erent concentrations of trastuzumab. Target cells incubated in complete medium alone or in 1% Triton X-100 were used to determine spontaneous and maximum 51 Cr release, respectively. A er 30 minutes, supernatants were collected and radioactivity was measured in a gamma counter (Cobra Quantum; PerkinElmer, Wellesley, MA). e mean percentage of speci c lysis of triplicate wells was calculated according to the following formula: (test release − spontaneous release)/(maximal release − spontaneous release) × 100.
Cytotoxicity assays. Cytotoxicity assays were performed as previously described. 45 Brie y, target cells were labeled with 51 Cr as described for the complement assay and mixed with decreasing numbers of e ector cells to give e ector to target ratios of 40:1, 20:1, 10:1, and 5:1. Target cells incubated in complete medium alone or in 1% Triton X-100 were used to determine spontaneous and maximum 51 Cr release, respectively. A er 4 hours, supernatants were collected and assessed as described for the complement assay.
Analysis of cytokine production and T-cell expansion. E ector T cells (HER2.CD28.ζ CAR expressing T cells and NT T cells) from healthy
donors were cocultured with HER2-positive and HER2-negative cell lines at a 1:1 e ector to target ratio in a 24-well plate. A er 24-48-hours incubation, culture supernatants were harvested and the presence of IFN-γ and IL-2 was determined by enzyme-linked immunosorbent assay as per the manufacturer's instructions (R&D Systems). T-cell expansion was determined by counting viable cells (Trypan blue exclusion) 7 days a er stimulation.
Xenogeneic mouse models. All animal experiments followed a protocol approved by the Baylor College of Medicine Institutional Animal Care and Use Committee. Animals were regularly examined for any signs of stress and euthanized according to preset criteria.
Intraperitoneal model: Recipient nonobese diabetic-SCID mice were purchased from Taconic (C.B-Igh-1b/IcrTac-Prkdcscid; FOX CHASE CB-17 SCID ICR; Taconic, Hudson, NY). Male 9-12-week-old mice were anesthetized with rapid sequence inhalation iso uorane (Abbott Laboratories, Maidenhead, England) followed by an intraperitoneal injection of 2 × 10 6 LM7.eGFP.FFLuc cells (in 200 µl PBS) on day 0. Starting on day 2 or 8 animals were treated with three daily intraperitoneal injections of 10 × 10 6 e ector cells (in 200 µl PBS).
Metastatic model: For the generation of a metastatic model of osteosarcoma, recipient Nu/Nu mice were purchased from Charles Rivers Laboratories (NU/NU-Foxn1 nu ; Charles River Laboratories, Wilmington, MA). Male 9-12-week-old mice were anesthetized with rapid sequence inhalation iso uorane (Abbott Laboratories) followed by tail-vein injection of 2 × 10 6 LM7.eGFP.FFLuc cells (in 200 µl PBS) on day 0. A er evidence of tumor establishment in the lungs on day 2, animals were treated with three daily tail-vein injections of 10 × 10 6 e ector cells (in 200 µl PBS).
Bioluminescence imaging. Iso uorane anesthetized animals were imaged using the IVIS system (Xenogen, Alameda, CA) 10 minutes a er 150 mg/ kg D-luciferin (Xenogen) was injected intraperitoneally. 42 e photons emitted from luciferase-expressing cells within the animal body and transmitted through the tissue were quanti ed using "Living Image, " a so ware program provided by the same manufacturer. A pseudocolor image representing light intensity (blue least intense and red most intense) was generated and superimposed over the grayscale reference image. Animals were imaged a er injections every other day, then twice weekly for 2 weeks then weekly therea er. Bioluminescence imaging ndings were con rmed by macroscopic examination as well as routine histology on euthanized animals. ey were regularly examined for any signs of stress and euthanized according to preset criteria, in accordance the Baylor College of Medicine's Center for Comparative Medicine guidelines.
Immunohistochemistry. Serial primary osteosarcoma samples were obtained from Texas Children's Hospital Pathology Department's archives and stained for phospho-HER2 immunohistochemistry using the same protocol as previously described. 46 To con rm in vivo imaging data, mice were euthanized by CO 2 inhalation, dissected then xed by immersion in 10% paraformaldehyde. Histology was performed on 10-µm serial horizontal sections. Tissue sections were stained by a standard hematoxylin and eosin technique. HER2 expression in xenogra s was detected by phospho-HER2 immunohistochemistry as previously described. 46 Statistical analysis. For the bioluminescence experiments, intensity signals were log-transformed and summarized using mean ± SD at baseline and multiple subsequent time points for each group of mice. Changes in intensity of signal from baseline at each time point were calculated and compared using paired t-tests or Wilcoxon signed-ranks test.
